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Pyrazinamide (PZA) is a key antituberculosis drug, yet no rapid susceptibility test is commercially available. PZA drug suscepti-
bility testing (DST) was performed directly on sputum samples from 327 patients and compared with the indirect method by
using the Bactec MGIT 960 system in the context of patient screening for participation in a drug trial. Compared to standard
indirect PZADST, direct DST was successful in only 59% of cases, but results obtained were highly accurate and available faster.
Agreement between the direct and indirect methods varied from 90 to 100% in each laboratory. The median times for obtaining
PZA results from the time when the specimen was collected ranged from 11 to 16 days for the direct test and 18 to 95 days for the
indirect test across laboratories. The direct method is accurate and reproducible across laboratories. It can be expected to accel-
erate results in>50% of cases, but it cannot replace indirect DST for PZA. Phenotypic methods remain the gold standard for
DST in drug trials. If future studies can optimize the method to decrease the number of uninterpretable results, direct MGIT
DST could be the new phenotypic DST standard for clinical trials, providing more rapid detection of resistance to new drugs in
experimental regimens.
Pyrazinamide (PZA) is a key antituberculosis (anti-TB) drugthat has recently been shown to substantially enhance the ac-
tivity of the novel agents bedaquiline (BDQ) and pretomanid (Pa)
(PA-824) in murine models of TB (1–3) and phase II studies (4–
6). Novel regimens based on the BDQ-PZA and Pa-PZA building
blocks do not include isoniazid (INH) and rifampin (RIF) and are
thus suitable for the treatment of multidrug-resistant TB (MDR-
TB) (defined as TB resistant to at least INH and RIF).
PZA resistance in subjects with TB susceptible to INH and RIF
is rare, i.e., 2% to 10% of non-MDR-TB cases in South Africa (7,
8) and elsewhere (9–11). In patients with MDR-TB, however, re-
cent studies have found between 60% and 70% PZA resistance in
South African trial centers (12). Clinical trials with a novel 3-drug
regimen such as BDQ-Pa-PZA in MDR-TB patients would re-
quire confirmed PZA susceptibility because undetected PZA re-
sistance exposes participants to the risk of acquisition of resistance
to the other agents in the tested regimen.
Although rapid molecular susceptibility tests for detection of
critical mutations directly in sputum samples are available for
most first-line and the most important second-line agents, there is
no commercial test for the rapid molecular detection of PZA re-
sistance. The association of multiple mutations throughout the
pncA gene with PZA resistance makes it difficult to design/develop
a test for detection of PZA resistance (13). Phenotypic PZA testing
in liquid culture medium is well established in clinical practice but
lacks accuracy and reproducibility (14). Most reports cite prob-
lems of false PZA resistance detection with the MGIT 960 system,
which is attributed to the inoculum concentration being too high
(13). Another limitation of the phenotypic method is the long
time to completion (15). This is due to the need to first grow a
primary culture and then grow a secondary culture with PZA at
the required concentration to determine phenotypic susceptibil-
ity. As an alternative to the indirect method, the test can be set up
directly from the clinical specimen. This eliminates the initial cul-
ture, thus speeding up the availability of test results, but such an
abbreviated procedure can lead to invalid results due to culture
contamination or insufficient growth if the inoculum contains too
few viable bacteria (15, 16). This method has been evaluated for
INH and RIF but not yet for PZA.
We investigated whether PZA testing via the automated Bactec
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MGIT 960 liquid culture system (Becton Dickinson Diagnostic
Systems, Sparks, MD) directly from sputum specimens is feasible
and accurate and expedites the availability of PZA susceptibility
results compared to the standard indirect method.
MATERIALS AND METHODS
Patient specimens and ethical approval. Spot sputum specimens were
collected from patients screened for eligibility to participate in a multi-
center phase II trial of a novel anti-TB regimen containing PZA (6). Pa-
tients were adults from community clinics with newly diagnosed smear-
positive pulmonary TB and no apparent concomitant illness or
conditions that would make participation inadvisable. Prior to the study,
one laboratory tested 31 consecutive specimens to validate direct MGIT
drug susceptibility testing (DST) for PZA. For the study, five mycobacte-
riology laboratories performed screening tests on sputum samples, among
which were acid-fast bacillus (AFB) smear microscopy, Genotype
MTBDRplus version 2 and MTBDRsl (Hain Lifescience, Nehren, Ger-
many), and direct MGIT DST for PZA (Becton Dickinson, Sparks, MD).
These screening tests were performed in parallel as capacity allowed as
long as the patient was still considered for participation based on micro-
biological or clinical criteria. Consequently, not all results were available
for every subject. Although direct MGIT DST for PZA was to be per-
formed on one specimen, two of the laboratories tested additional speci-
mens (day 2 and day 1). Also, the intention was to test only smear-
positive specimens; however, smear-negative specimens were tested, as
the smear results were not always available before setup of direct DST. The
institutional review boards of all the participating sites approved the
study. Written informed consent for study participation was obtained
from all patients.
Bactec MGIT drug susceptibility testing methods. Direct and indi-
rect PZA susceptibility testing was performed as described previously by
Siddiqi et al. and according to the manufacturer’s instructions, respec-
tively (15, 17). For the direct method, sputum specimens were processed
by using the N-acetyl-L-cysteine–sodium hydroxide (NALC-NaOH)
method, using a final concentration of 1 to 1.5% NaOH. The remaining
pellet was resuspended in phosphate buffer (pH 6.8) up to a final volume
of 2 ml and was used as the inoculum for PZA susceptibility testing. The
resuspended pellet was diluted 1/10, and 0.5 ml was inoculated into the
control tube (also containing polymyxin B, amphotericin B, nalidixic
acid, trimethoprim, and azlocillin [PANTA] and the PZA enrichment
supplement), while 0.5 ml of the undiluted resuspended pellet was inoc-
ulated into the tube containing 100 g/ml PZA (and also containing
PANTA and the PZA enrichment supplement). Tubes were incubated in
the Bactec 960 MGIT instrument, according to the 21-day protocol for
PZA susceptibility testing (17). Direct DST results from the MGIT instru-
ment were recorded as susceptible (S), resistant (R), or uninterpretable
(U). Indirect DST results were recorded as susceptible or resistant, since
tests with uninterpretable results were repeated until valid results were
obtained. If the direct or indirect PZA result was resistant, the PZA tube
was checked visually for evidence of contamination, and a Ziehl-Neelsen
stain and/or blood agar plate assay was performed to rule out contami-
nants. If contaminants were found, the result was reported as uninterpre-
table. Uninterpretable results were therefore classified as contaminated
(including X400 errors reported by the MGIT instrument), growth failure
(X200 errors due to insufficient growth, i.e., that the growth units of the
control did not reach 400 within 21 days), or instrument failure.
Data analysis and statistics. The indirect result was regarded as the
gold standard. Although there was a laboratory protocol, variations in the
number and timing of direct and indirect tests performed were observed
among laboratories. Laboratory 4 had duplicate indirect PZA results; only
one result was considered for agreement analysis since duplicate indirect
tests all gave the same results. For laboratories 2 and 5, direct tests were
repeated up to 3 times on different screening specimens: only the pair
where both direct and indirect tests were done on the same specimen was
kept. For laboratory 4, direct tests were done on a separate specimen from
that used in indirect tests; direct tests were done once, and indirect tests
were repeated up to 2 times and paired as described above. No duplicate
tests were done for direct tests or indirect tests in laboratory 3.
In order to calculate the direct MGIT success rate (reportable results),
the reproducibility of replicate direct MGIT results, and the time to direct
and indirect DST results, all test results were used. To calculate the agree-
ment between the direct and indirect test results, the results were paired as
described above. The time between the specimen collection date and the
ultimate PZA result date was calculated regardless of whether the result
was interpretable or not. No times were available for the validation study.
All direct DST was performed within 48 to 72 h of specimen receipt in the
laboratory, except for one laboratory. Sputum specimens were processed
for MGIT culture within the same time frame. However, the time from
determination of an M. tuberculosis-positive MGIT culture to the setup of
indirect PZA DST varied.
Category agreement was calculated by dividing the number of cate-
gorical result matches (susceptible/resistant) by the total number tested
(18). A chi-square test was used to compare proportions. Correlation was
measured by using the Spearman rank correlation coefficient. SPSS soft-
ware version 20 (SPSS Corporation, Chicago, IL) was used for all analyses.
RESULTS
Performance. Validation was performed with 31 sputum speci-
mens. Of these, 24 (77.4%) had reportable PZA results, 17 suscep-
tible and 7 resistant, with an agreement of 100% between the re-
sults of the direct and indirect methods. The 7 uninterpretable
results were due to growth failure in 6 cultures (85.7%) and con-
tamination in 1 culture (14.3%) (Table 1).
PZA susceptibility testing was performed on sputum samples
from 327 patients: 398 tests were performed by the direct method,
and 207 were performed by the indirect method (Table 1). The
direct PZA test results were uninterpretable for 163 samples
(41.0%), varying from 23% to 66% among the five laboratories.
Reasons for uninterpretable PZA direct testing results were
growth failure for 67.5%, contamination for 31.9%, and instru-
ment failure for 0.6% (for the distribution among laboratories, see
Table 1). Of 398 direct PZA tests done, 348 had smear results
available (87.4%): 36 were smear negative (10.3%) and were more
likely to give an uninterpretable PZA direct testing result (33 un-
interpretable results [91.7%]), compared to 312 positive smear
specimens (110 uninterpretable results [35.3%]; chi square 
42.4; P 0.001). This was due mainly to insufficient growth: 30 of
the 33 uninterpretable results were due to X200 errors (91%). A
correlation between smear grading and the proportion of uninter-
pretable PZA results was also observed (Spearman correlation 
0.298; P 0.001) (Fig. 1).
Agreement and reproducibility. For all laboratories, an anal-
ysis of pairs (1 direct test result and 1 indirect test result per pa-
tient, as described in Materials and Methods) revealed that PZA
resistance was detected in 12/139 (8.6%) pairs by the direct
method and in 13/139 (9.4%) pairs by the indirect method. Of
these 139 pairs, 134 were in agreement, and 5 were not, for 96.4%
category agreement. Two of the discrepant results were resistant
by the direct test and susceptible by the indirect test, while three
were susceptible by the direct test and resistant by the indirect test
(Table 1). No further testing was done to determine the true na-
ture of this discordance.
Two laboratories performed direct tests in duplicate or triplicate.
One had 20 sets of duplicate results (15 S/S and 5 R/R), showing 100%
concordance. The other laboratory had 69% concordant results (9/13
[1 S/S/S, 1 R/R/R, and 7 uninterpretable {5 U/U and 2 U/U/U}]), 31%
results with uninterpretable values (4/13 [1 S/S/U and 3 S/U/U]), and
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no discordant results. Only one laboratory performed indirect tests in
duplicate: 11 results were concordant (1 R/R and 10 S/S), 1 result had
and uninterpretable value (contaminated/susceptible), and there
were no discordant results.
Time to availability of results. The median times to availabil-
ity of results for each laboratory ranged from 11 to 16 days for the
direct test, compared to 18 to 95 days for the indirect test (Table
1). Table 2 compares the numbers of direct PZA tests with results
available (reportable or uninterpretable) 7, 14, 21, and 28 days
after specimen collection. Variable times were observed, with
96% of the results being available at 21 days (i.e., the maximum
duration for the MGIT PZA protocol) for 3 of the 4 laboratories.
Such a comparison was not done for indirect PZA test results since
the indirect tests were often not set up in real time.
DISCUSSION
In this multicenter clinical trial of a novel anti-TB treatment reg-
imen, we compared PZA resistance testing performed directly on
TABLE 1 Summary of direct and indirect PZA test resultsa
Parameter
Value for laboratory
1 (validation
study) 2 3 4 5
Total (not including
validation study)
No. of patients 31 23 13 52 239 327
No. of indirect PZA tests 31 23 13 37 140 207
No. of direct PZA tests 31 47 13 51 287 398
No. of reportable direct PZA test
results/total no. of direct tests
done (%)
24/31 (77.4) 16/47 (34) 10/13 (76.9) 30/51 (58.8) 179/287 (62.4) 235/398 (59.0)
No. of uninterpretable direct PZA test
results/total no. of direct tests
done (%)
7/31 (22.6) 31/47 (66) 3/13 (23.1) 21/51 (41.2) 108/287 (37.6) 163/398 (41.0)
No. of uninterpretable direct PZA test
results/total no. of uninterpretable
results (%) caused by:
X200 error (growth failure) 6/7 (85.7) 16/31 (51.6) 2/3 (66.7) 16/21 (76.2) 76/108 (70.4) 110/163 (67.5)
Contamination 1/7 (14.3) 15/31 (48.4) 1/3 (33.3) 5/21 (23.8) 31/108 (28.7) 52/163 (31.9)
Instrument failure 1/108 (0.9) 1/163 (0.6)
Direct results
Median time (days) from date of
collection to date of start of PZA
testing (range)
NA 0 (0–0) 1 (0–3) 0 (0–3) 2 (0–35)
Median time (days) from date of
start of direct PZA testing to date
of direct PZA test result (range)
NA 16 (3–29) 10 (7–21) 13 (5–25) 14 (1–25)
Median time (days) from date of
collection to date of PZA test
result (range)
NA 16 (3–29) 11 (7–21) 13 (5–25) 16 (2–49)
Indirect results
Median time (days) from date of
collection to date of start of PZA
testing (range)
NA 88 (7–208) 29 (5–127) 48 (14–112) 11 (5–187)
Median time (days) from date of
start of indirect PZA testing to
date of indirect PZA test result
(range)b
NA 7 (5–13) 7 (7–14) 8 (6–16) 7 (5–19)
Median time (days) from date of
collection to date of PZA test
result (range)
NA 95 (14–213) 40 (12–141) 59 (21–126) 18 (11–195)
No. of pairs of direct/indirect results
(interpretable results only)
24 10 10 10 109 139
No. of pairs in agreement; no. of
pairs not in agreement
24 (17 S, 7
R); 0
10 (8 S, 2 R); 0 10 (10 S, 0 R); 0 9 (9 S, 0 R); 1 (direct
R and indirect S)
105 (97 S, 8 R); 4 (1
direct R and
indirect S; 3
direct S and
indirect R)
134 (124 S, 10 R); 5 (2
direct R and
indirect S; 3 direct
S and indirect R)
% agreement 100 100 100 90.0 96.3 96.4
a Proportion of reportable direct PZA test results that are either smear negative, scanty, 1, 2, or 3. S, susceptible; R, resistant; NA, not applicable.
b The difference between the PZA test start date and the PZA test result date does not include the time initially required to obtain a positive culture.
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sputum specimens from untreated patients with indirect testing
using the Bactec MGIT 960 system. This evaluation was done in
the context of time pressures dictated by the need for patients to be
evaluated for participation and started on treatment without de-
lay. The observed category agreement between the direct and in-
direct methods (the reference method or gold standard) was ex-
cellent, ranging from 90 to 100% per laboratory. Only 5 discrepant
results for 139 pairs (3.6%) were observed, similar to the discor-
dance rate observed previously for direct testing of INH (4.9%)
and RIF (3.9%) resistance by Siddiqi et al. (15). The reproducibil-
ity of the direct method was excellent, although the numbers are
too small to compare and confirm differences.
Compared to standard indirect PZA DST, direct DST was suc-
cessful in 59% of cases (range across laboratories of 34% to 77%).
The reason(s) for the variable performance among all laboratories
is inexplicable. Performance was exceptionally poor in one labo-
ratory, with the number of uninterpretable results equally being
due to insufficientM. tuberculosis density and contamination. The
drug susceptibility testing failures could be attributed to poor
techniques for processing of sputum specimens resulting in inad-
equately digested and decontaminated specimens. Resuspension
of the sputum pellet is another critical step to ensure an even
distribution of M. tuberculosis bacteria and representative sam-
pling for smear microscopy and culture inoculation. This was the
first time that these laboratories performed the direct MGIT drug
susceptibility test method, and no on-site training was provided
prior to the performance of the study.
The 59% feasibility rate is lower than the rate reported in a
recent study where direct susceptibility testing of M. tuberculosis
for INH and RIF resistance using the same MGIT system in four
laboratories yielded reportable results for 85% of 360 AFB smear-
positive sputum specimens (15). As reported previously by Sid-
diqi et al., the most frequent reason for our uninterpretable direct
test results was growth failure. In their study, a 4- to 21-day pro-
FIG 1 Reportable and uninterpretable PZA direct test results according to smear grading. The grading scale was based on WHO guidelines, as follows: negative
(0 colonies/100 fields), scanty (1 to 9 colonies/100 fields), 1 (10 to 99 colonies/100 fields), 2 (1 to 10 AFB/field), or 3 (10 AFB/field).
TABLE 2 Numbers of direct PZA tests with results available (reportable
or uninterpretable) 7, 14, 21, and 28 days after specimen collection
Laboratory Day
No. of direct
PZA tests
with results
available
No. of direct PZA
test results
available/total no.
of direct PZA
tests performed
% of direct PZA tests
with results available
2 7 12 12/47 25.5
14 11 23/47 48.9
21 22 45/47 95.7
28 1 46/47 97.9
3 7 2 2/13 15.4
14 9 11/13 84.6
21 2 13/13 100.0
28 0 13/13 100.0
4 7 8 8/48 16.7
14 20 28/48 58.3
21 18 46/48 95.8
28 2 48/48 100.0
5 7 7 7/269 2.6
14 89 96/269 35.7
21 100 196/269 72.9
28 66 262/269 97.4
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tocol was used instead of the standard 4- to 13-day protocol for the
INH and RIF indirect tests, to allow more time for the growth
control tube to reach the required 400 growth units for a valid test.
The indirect PZA test protocol is 4 to 21 days long; the extended
incubation time allows more time for the M. tuberculosis bacteria
to grow if the growth rate in the slightly acidified MGIT PZA
medium is lower. The same protocol was used for the direct PZA
test since it was not possible to adjust the instrument protocol, i.e.,
extend it beyond 21 days, using the Bactec MGIT Epicenter sys-
tem, which was not available in these laboratories. Slow growth of
some M. tuberculosis strains in PZA medium may have been a
cause for growth failures. It is more likely that the reason for in-
sufficient growth in the control was that the inoculum density was
too low. Although the inoculum for the control tube is a 1/10
dilution of the sputum pellet, instead of the 1/100 dilution used in
the indirect test, the concentration of viable M. tuberculosis bacte-
ria may have been very low in some sputum specimens despite
these specimens being smear positive. Furthermore, it is possible
that some strains had a delayed lag time before the beginning of
replication and did not reach the threshold of detection before the
end of the protocol.
Several approaches for decreasing the number of uninterpre-
table results can be considered. For the contaminated cultures, the
amount of antimicrobial mixture (PANTA), which is added to the
control and PZA-containing tubes, could be increased to enhance
the suppression of contaminants. To decrease growth failures, a
smaller dilution of the sputum sediment could be evaluated as the
inoculum for the control, i.e., the use of a 1/5 dilution instead of a
1/10 dilution. Since the number of M. tuberculosis bacteria in the
sputum sediment is lower than that in a positive MGIT culture
used for indirect testing, the proportions of organisms between
the control and drug tubes should still be appropriate with the 1/5
dilution.
The median times for each laboratory to obtain PZA results
from the time of specimen collection ranged from 11 to 16 days for
the direct test, compared to 18 to 95 days for the indirect test
(Table 1). In three laboratories where the direct PZA test was set
up within 3 days of specimen collection and results were often
available before the end of the 21-day protocol, the turnaround
time was 21 days for 96% of specimens (Table 2). The longer
turnaround time in laboratory 5 was due to the laboratory being
busy and prolonging the setup of the direct test. Longer delays
were observed for the indirect results when contaminated MGIT
cultures had to be decontaminated and recultured and pure M.
tuberculosis growth had to be obtained before repeat DST. Logis-
tical problems, such as heavy workload along with insufficient
laboratory staff and accessibility to biosafety cabinets, also con-
tributed to the delay in the setup of indirect DST. The time to
obtain results after the test was set up ranged from 10 to 16 days for
direct tests, compared to 7 to 8 days for indirect tests. A longer
time to a result for direct tests is expected, as the inoculum density
is smaller, especially for tests that do not reach the growth unit
threshold by the end of the 21-day protocol. In a study of INH/RIF
direct MGIT testing (15), similar results were obtained: 8 to 14
days for direct test results and 6 to 10 days for indirect test results.
However, in the study by Siddiqi et al., the uninterpretable results
were not included in the analysis of the time to a positive result
(final results). It is likely that uninterpretable results would have a
longer time to positive results. Our direct test result times, with
and without uninterpretable results, are comparable to those re-
ported for INH and RIF susceptibility testing, suggesting that M.
tuberculosis grows at the same rate in MGIT PZA medium as in the
MGIT medium used for INH and RIF testing.
Phenotypic methods remain the gold standard for DST in clin-
ical trials, and past and current trials depend on phenotypic test-
ing of anti-TB drugs to ensure that study participants are suscep-
tible to the drugs that they are receiving. Having reliable
susceptibility results for the study drugs within the screening pe-
riod, e.g., 2 to 3 days, would be a significant advancement for
clinical trials. Currently, the mechanism or molecular basis of
drug resistance is not known for some of the second-line drugs
and new TB drugs like bedaquiline, sutezolid, pretomanid (PA-
824), and delamanid. Furthermore, not all gene targets associated
with resistance are known (e.g., INH, fluoroquinolones, and in-
jectables). Therefore, until current molecular tests are improved
or new ones are developed, a rapid phenotypic method like the
direct MGIT system would be preferable to indirect MGIT testing.
Phenotypic methods may be replaced in the future with molecular
tests; however, until we know the relationship between resistance
mutations, MICs, and clinical outcomes, there will be a need for
phenotypic testing to determine MICs. Rapid MIC determina-
tions are possible with the direct MGIT method (K. Eisenach,
unpublished data).
Our study, being conducted in the context of a clinical trial,
was limited by the variations in the number and timing of tests in
the participating laboratories. However, our results show that
once reportable results are obtained, they are reliable and can be
obtained in different laboratories. Additional studies with PZA are
needed to investigate whether the frequency of uninterpretable
results can be decreased by optimizing the method and to gain
more experience with MDR-TB/XDR-TB (extensively drug-resis-
tant TB) sputum specimens. If future studies provide reproduc-
ible and conclusive data, direct MGIT DST could be the new phe-
notypic DST standard for clinical trials and clinical management
not only for PZA but also for new drugs in clinical development.
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